This review highlights emerging therapeutic strategies aimed at increasing adiponectin levels to mitigate cardiovascular risk in metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Potential adiponectin-raising therapies warrant investigation in metabolic syndrome; leaves open impact on cardiovascular outcomes.
Changes in diagnostic criteria have impacted on the definition of the metabolic syndrome. The central aetiological importance of insulin resistance has lessened, while the role of other cardiovascular risk factors has progressively increased. Inflammatory mediators have also been identified as crucial targets for more selective therapies in metabolic syndrome. Among several pro-inflammatory factors, adiponectin has been shown to be associated with reduced cardiovascular risk in metabolic syndrome patients. Here, we review new therapeutic approaches, which could potentially increase adiponectin levels in metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Montecucco et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: